Moleculin Biotech Stock Price Prediction
| MBRX Stock | USD 2.69 0.07 2.67% |
Oversold Vs Overbought
50
Oversold | Overbought |
EPS Estimate Next Quarter (1.54) | EPS Estimate Current Year (14.09) | EPS Estimate Next Year (5.28) | Wall Street Target Price 18 | EPS Estimate Current Quarter (2.44) |
Using Moleculin Biotech hype-based prediction, you can estimate the value of Moleculin Biotech from the perspective of Moleculin Biotech response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Moleculin Biotech to buy its stock at a price that has no basis in reality. In that case, they are not buying Moleculin because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Moleculin Biotech after-hype prediction price | USD 2.64 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Moleculin |
Moleculin Biotech After-Hype Price Prediction Density Analysis
As far as predicting the price of Moleculin Biotech at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Moleculin Biotech or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Moleculin Biotech, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Moleculin Biotech Estimiated After-Hype Price Volatility
In the context of predicting Moleculin Biotech's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Moleculin Biotech's historical news coverage. Moleculin Biotech's after-hype downside and upside margins for the prediction period are 0.13 and 8.23, respectively. We have considered Moleculin Biotech's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Moleculin Biotech is risky at this time. Analysis and calculation of next after-hype price of Moleculin Biotech is based on 3 months time horizon.
Moleculin Biotech Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Moleculin Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Moleculin Biotech backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Moleculin Biotech, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.24 | 5.64 | 0.05 | 0.14 | 9 Events / Month | 8 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
2.69 | 2.64 | 1.86 |
|
Moleculin Biotech Hype Timeline
Moleculin Biotech is now traded for 2.69. The entity has historical hype elasticity of -0.05, and average elasticity to hype of competition of -0.14. Moleculin is projected to decline in value after the next headline, with the price expected to drop to 2.64. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -1.86%, whereas the daily expected return is now at 0.24%. The volatility of related hype on Moleculin Biotech is about 970.55%, with the expected price after the next announcement by competition of 2.55. About 15.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.05. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Moleculin Biotech recorded a loss per share of 12.04. The entity last dividend was issued on the 1st of February 2021. The firm had 1:15 split on the 22nd of March 2024. Given the investment horizon of 90 days the next projected press release will be in about 9 days. Check out Moleculin Biotech Basic Forecasting Models to cross-verify your projections.Moleculin Biotech Related Hype Analysis
Having access to credible news sources related to Moleculin Biotech's direct competition is more important than ever and may enhance your ability to predict Moleculin Biotech's future price movements. Getting to know how Moleculin Biotech's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Moleculin Biotech may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| DRUG | Bright Minds Biosciences | (9.63) | 9 per month | 4.62 | 0.14 | 9.23 | (11.87) | 1,471 | |
| HPQ | HP Inc | 0.51 | 9 per month | 1.62 | 0.02 | 2.22 | (2.63) | 6.13 | |
| INTC | Intel | (0.30) | 6 per month | 2.58 | 0.06 | 6.36 | (3.50) | 18.29 | |
| CVX | Chevron Corp | 1.42 | 6 per month | 1.05 | 0.02 | 2.21 | (1.79) | 5.13 | |
| KO | The Coca Cola | 0.69 | 8 per month | 0.00 | (0.30) | 1.11 | (1.66) | 4.00 | |
| TRV | The Travelers Companies | (0.41) | 7 per month | 1.17 | 0.09 | 1.93 | (2.17) | 11.31 | |
| JNJ | Johnson Johnson | 0.08 | 7 per month | 0.00 | (0.26) | 1.40 | (1.42) | 3.25 | |
| JPM | JPMorgan Chase Co | (2.36) | 8 per month | 1.42 | 0.05 | 2.05 | (2.00) | 15.87 | |
| MSFT | Microsoft | 4.77 | 8 per month | 1.49 | (0.05) | 2.09 | (1.85) | 8.19 |
Moleculin Biotech Additional Predictive Modules
Most predictive techniques to examine Moleculin price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Moleculin using various technical indicators. When you analyze Moleculin charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Moleculin Biotech Predictive Indicators
The successful prediction of Moleculin Biotech stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Moleculin Biotech, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Moleculin Biotech based on analysis of Moleculin Biotech hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Moleculin Biotech's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Moleculin Biotech's related companies. | 2021 | 2022 | 2024 (projected) | Net Debt To EBITDA | 3.1 | 1.4 | 0.94 | Intangibles To Total Assets | 0.13 | 0.19 | 0.45 |
Story Coverage note for Moleculin Biotech
The number of cover stories for Moleculin Biotech depends on current market conditions and Moleculin Biotech's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Moleculin Biotech is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Moleculin Biotech's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Moleculin Biotech Short Properties
Moleculin Biotech's future price predictability will typically decrease when Moleculin Biotech's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Moleculin Biotech often depends not only on the future outlook of the potential Moleculin Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Moleculin Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2 M | |
| Cash And Short Term Investments | 23.6 M |
Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.